BioLargo, Inc. develops and commercializes sustainable technologies across cleantech, environmental engineering, water treatment and life sciences. Company updates commonly cover its Aqueous Electrostatic Concentrator, a PFAS treatment technology designed to remove and collect per- and polyfluoroalkyl substances from liquid streams, as well as engineering services and project work in water, wastewater, remediation and minerals processing.
BioLargo news also follows subsidiary activity, including Clyra Medical Technologies and its FDA-cleared wound care products based on Copper-Iodine Complex Technology, distribution partnerships for ViaCLYR, investor communications, annual operating results, and commercialization updates across medical, environmental and battery-related business lines.
BioLargo, Inc. (OTCQB:BLGO) released its Q2 2020 highlights, coinciding with its 10-Q filing. The company launched Clyraguard, an FDA-registered disinfectant, achieving strong sales growth. It secured a $1 million inventory line and established distribution partnerships. Upcoming projects include a $500,000 revenue-generating AOS water treatment contract and field pilots for PFAS treatment technology. Despite a 2% revenue decrease in Q2, overall revenue rose 8% for the first half of 2020. BioLargo has converted $3.5 million of debt to equity, strengthening its balance sheet.